In:
Haematologica, Ferrata Storti Foundation (Haematologica), ( 2023-07-13)
Kurzfassung:
In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved a superior clinical benefit over Pd with a manageable toxicity profile, leading to its approval in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI).
We report here a real-world experience of 200 RRMMs treated with EloPd in 35 Italian centers outside of clinical trials. In our dataset, the median number of prior lines of therapy was 2, with 51% of cases undergoing autologous stem cell transplant (ASCT) and 73% exposed to daratumumab. After a median follow-up of 9 months, 126 patients stopped EloPd, most of them (88.9%) because of disease progression. The overall response rate (ORR) was 55.4%, in line with the pivotal trial results. Regarding adverse events, our cohort experienced a toxicity profile similar to the ELOQUENT-3 trial, with no significant differences between younger (
Materialart:
Online-Ressource
ISSN:
1592-8721
,
0390-6078
DOI:
10.3324/haematol.2023.283251
Sprache:
Unbekannt
Verlag:
Ferrata Storti Foundation (Haematologica)
Publikationsdatum:
2023
ZDB Id:
2186022-1
ZDB Id:
2030158-3
ZDB Id:
2805244-4